Fideuram - Intesa Sanpaolo Private Banking S.P.A. 13F: Adds $7.7M to BIIB Stake
Key Points
- Fideuram - Intesa Sanpaolo Private Banking S.P.A. grew its Biogen Inc. position by 223.6% in an October 22, 2026 filing, ending the period with 49,319 shares valued at $11,140,180.
- Biogen Inc. trades near $250.86, sitting above its 50-day moving average of $221.68 and its 200-day moving average of $198.77 as it heads toward its upcoming October 28 earnings report.
- Wall Street analysts hold a buy consensus on the stock, backed by recent price target adjustments from firms like UBS, JP Morgan, and Wells Fargo.
Get Biogen text alerts
We text you when insiders, Congress, analysts or big funds move on $BIIB.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures
Fideuram - Intesa Sanpaolo Private Banking S.P.A. significantly grew its investment in Biogen Inc. BIIB, according to a Form 13F filing with the Securities and Exchange Commission on October 22, 2026.
BIIB
Biogen Inc.
Fideuram - Intesa Sanpaolo Private Banking S.P.A. vs. the S&P 500
Hypothetical returns from Fideuram - Intesa Sanpaolo Private Banking S.P.A.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Fideuram - Intesa Sanpaolo Private Banking S.P.A.'s Biogen Position
The private banking firm increased its holdings by 34,081 shares, marking a 223.7% jump from its previous count of 15,238 shares. That brought its total stake to 49,319 shares, with a reported value of $11,140,180 at the time of the filing. Biogen shares closed at $253.84 on the filing date.
Other Institutional Activity in Biogen
Other major institutional investors adjusted their positions in the drug maker around the same period. Pictet North America Advisors opened a new position with 2,865 shares worth about $647,146. Van Eck Associates grew its holdings by 14,245 shares, ending with 1,079,861 shares worth about $233,930,293. Man Group reduced its stake by 20,539 shares, leaving it with 318,745 shares valued at roughly $69,049,731. Meanwhile, Primecap Management Company added 396,980 shares for a final tally of 15,154,606 shares worth about $3,846,845,131.
Biogen Inc. Stock Up 4.1%
Biogen shares recently traded around $250.86, sitting well above both its 50-day moving average of $221.68 and its 200-day moving average of $198.77. The stock trades near the top of its 52-week range, which spans from a low of $138.00 to a high of $246.54.
Recent Earnings
Biogen reported trailing twelve month revenue of $10.03 billion alongside earnings of $5.63 per share. The healthcare company operates with a net profit margin of 8.3% and a return on equity of 4.6%. Investors look ahead to the company's next earnings report scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
Company insiders have made several trades over recent months. Officer Priya Singhal sold 2,660 shares at an average price of $199.83 on February 9, 2026, totaling $531,548. Officer Nicole Murphy bought 3 shares at $195.04 on February 12, 2026, worth $585. Director Lloyd B. Minor sold 1,186 shares on August 4, 2026, valued at $239,750.
Analysts Set New Price Targets
Wall Street firms have actively updated their views on the stock. On October 9, UBS maintained its buy rating and raised its target to $270.00. JP Morgan upgraded the stock to overweight with a $300.00 target on October 12. Wells Fargo kept an overweight rating on October 20 with a $310.00 target, while TD Cowen maintained a buy rating and lifted its target to $250.00 on October 21. B of A Securities maintained a neutral rating with a $244.00 target on October 22. The stock holds a consensus buy rating from 32 analyst opinions with a mean target price of $247.32.
About Biogen Inc.
Based in Cambridge, Massachusetts, Biogen Inc. develops and delivers therapies for neurological and rare diseases worldwide. The company focuses on discovering advanced medical treatments and brings in billions in annual revenue, making it a closely watched name in the healthcare sector.
Bottom Line
Fideuram's substantial increase highlights steady institutional interest in Biogen as the company approaches its late October earnings announcement. Observers will monitor upcoming quarterly numbers and continued institutional filings for further direction.
Related Filing Alerts
Source: Fideuram - Intesa Sanpaolo Private Banking S.P.A.'s 13F filing on $BIIB (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts